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Background: Post infectious chronic cough is a disabling illness. In 2009 an influenza pandemic
occurred due to a novel strain of H1N1 influenza. Prolonged symptoms such as chronic cough
remaining after the infection has cleared have not been examined. This study sought to inves-
tigate the prevalence, characteristics and mechanism of chronic cough following laboratory-
confirmed H1N1 2009 influenza.
Methods: Out of 836 eligible patients who had been tested by PCR assay for H1N1, 136
responders participated. Nineteen underwent detailed clinical investigation of cough, and
airway function using symptom questionnaires, hypertonic saline challenge, and cough moni-
toring.
Results: Post H1N1 chronic cough was reported by 43%, and chronic cough after non-H1N1
infection was present in 36% of participants. In the participants who progressed to testing
objectively measured cough frequency was 3 times greater; there was a 9-fold increase in
cough reflex sensitivity and greater quality of life impairment in the participants with postin-
fectious chronic cough following H1N1 infection than for the participants with no coughnverting enzyme Inhibitor; ARI, Acute Respiratory Illness; CRS, Cough Reflex Sensitivity; DRS, Dose
acic Airway Hyperresponsiveness-Dose Response Slope; GORD, Gastro Oesophageal Reflux Disease;
er Cough Questionnaire; LDQ, Laryngeal Dysfunction Questionnaire; UTCPDCUM15Coughs, Urge to Cough
ve 15 coughs; Snot-20, 20-item sino-nasal outcome test; VAS, Visual Analogue Scale.
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Postinfectious H1N1 chronic cough 139following H1N1 infection and for the healthy controls.
Conclusions: This study reports the first evaluation of chronic cough following H1N1 infection.
Patients that develop chronic cough after H1N1 infection display increased cough reflex sensi-
tivity up to 220 days after confirmed infection. There is an absence of associated risk factors
and less impairment in quality of life compared to those patients normally seen in a specialist
cough clinic. The associated mechanism was found to be cough reflex hypersensitivity.
Trial Registration: This clinical trial has been registered with the Australian New Zealand Clin-
ical Trials Register, ACTRN12610000540011.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Post infectious chronic cough is a disabling illness that can
occur following respiratory tract infection1 due to laryngeal
dysfunction2,3 or bronchial hyperresponsiveness.4 An influ-
enza pandemic occurred in 2009 due to a novel strain of H1N1
influenza.5e7 The influenceofpandemic 2009H1N1onchronic
cough is not described. Pandemic 2009 H1N1 virus derives six
genes from triple-reassortant North American swine virus
lineages and two genes (encoding neuraminidase and matrix
proteins) from Eurasian swine virus lineages.8 In experimen-
tally infected animals, the level of pulmonary replication of
the 2009 H1N1 virus has been higher than that of seasonal
influenza A (H1N1) viruses9e11 but the virus generally lacks
mutations that are associated with increased pathogenicity
in other influenza viruses. Initial cases of H1N1 infectionwere
identified in March 2009, and by March 2010 almost all
countries had reported H1N1 cases. An estimated 59 million
illnesses, 265 000 hospitalisations, and 12 000 deaths had
been caused by the 2009 H1N1 virus as of mid-February 2010.
In contrast, in a normal influenza season with an ordinary
strain of influenza, there are 200 000 cases and 36 000 deaths
in only a few months in the United States alone each year.6
Most illnesses caused by H1N1 infection during the
pandemic have been reported as acute and self-limited,with
a higher prevalence amongst children and young adults. The
typical presentation is with fever and acute cough that may
be accompanied by sore throat and rhinorrhea. Gastroin-
testinal symptoms including nausea, vomiting, and diarrhoea
have been reported to be more common than in seasonal
influenza.5,7 To date, prolonged symptoms such as chronic
cough remaining after the infection has cleared have not
been examined. This study sought to investigate the char-
acteristics and mechanism of chronic cough following
laboratory-confirmed H1N1 2009 influenza compared to
participants without cough after H1N1 2009 influenza and
with healthy controls. We hypothesised that the character-
istics of postinfectious chronic cough following H1N1 infec-
tion would be similar to other postinfectious chronic cough
and be associated with cough reflex hypersensitivity.Methods
Subjects
Eligible participants were asymptomatic with no cough
symptoms prior to infection and had received H1N1influenza testing by the Hunter Area Pathology Service at
least 8 weeks prior to completion of the symptoms ques-
tionnaire, were aged above 18 years, and gave their written
and free consent to participate in the study. Ineligible
participants were pregnant or breast feeding women,
current smokers and those who had a current active
respiratory disease such as COPD, asthma or bronchiectasis
and/or were unable to attend study visits.
Study design
H1N1 2009 influenza testing by multiplexed tandem poly-
merase chain reaction (MT-PCR) was available to residents
of the Hunter region of NSW, Australia with symptoms of an
acute respiratory tract infection suspected as influenza,
from 20th June 2009 onwards. Over this period test
requests came from both outpatients and inpatients with
influenza-like illness. The testing was performed by the
Hunter Area Pathology Service (HAPS) located at John
Hunter Hospital in Newcastle, New South Wales (NSW)
Australia. During October 2009, the HAPS database was
used to identify people who had been tested for H1N1 2009
influenza by MT-PCR assay at least 8 weeks previously.
These people were then sent a letter of invitation and
a study information and consent sheet requesting that they
identify current symptoms including cough, breathing
difficulties and voice changes, and current cough severity
which was scored on a visual analogue scale (VAS) 100 mm
in length with 0 representing “no cough” to 100 repre-
senting “worst cough”. Eight hundred and thirty six letters
were sent and 136 responded by completing the current
symptoms form. Nineteen of these progressed to clinical
testing at the hospital.
Clinical investigations
Nineteen participants completed a range of investigations
to assess cough and airway function. These consisted of the
Cough VAS12,13 for cough severity, the Leicester cough
questionnaire (LCQ),14 Cough Reflex Sensitivity (CRS) using
4.5% hypertonic saline challenge15,16 and cough frequency
measured during the clinic visit by a cough recording
monitor.17,18 Upper airway dysfunction was assessed by the
Laryngeal dysfunction questionnaire (LDQ)19,20 and hyper-
tonic saline challenge for extrathoracic airway hyper-
responsiveness (EAHR).21,22 Bronchial hyperresponsiveness
(BHR) was assessed using spirometry and hypertonic saline
challenge.22 To investigate prevalence of risk factors
Table 1 H1N1 laboratory tested participant
characteristics.
Pos H1N1 Neg H1N1 P value
N (%) 58 78
Gender, M/F 16/42 38/40 0.013
Age, yr Mean  SD 38.4  18.1 53.7  23.3 0.0001
Time, days (swab to
questionnaire letter)
Median (IQR)
103.5 (34.0) 100.5 (24.0) 0.13
Cough (%) 43.1 35.9 0.39
Breath (%) 25.9 30.8 0.53
Voice (%) 27.6 16.7 0.12
Cough Severity,
Mean  SD
43.0  23.1 49.0  25.0 0.38
140 N.M. Ryan et al.associated with persistent cough and upper airway
dysfunction, the following questionnaires were also
completed: Rhinosinusitis (SNOT-20),23 Gastroesophageal
reflux disease (GORD),24 ACE-I use, and Obstructive Sleep
Apnoea (Berlin Questionnaire).25
All subjects provided written informed consent for this
study, which was approved by the University of Newcastle’s
Human Research Ethics Committee and the Hunter New
England Human Research Ethics Committee.
Clinical methods
Multiplexed tandem polymerase chain reaction Method
Influenza MT-PCR testing on pooled nose and throat swabs
was performed by the MT-PCR method targeting influenza A
and B nucleoprotein and influenza A hemagglutinin gene
sequences. The assay has a synthetic internal control
sequence to act as an amplification control.26 Control
influenza RNA for influenza A strains, including pandemic
strain 2009 H1N1 was run in parallel. The results distin-
guished influenza A (seasonal strains), influenza 2009 H1N1
and influenza B.
Pulmonary function test with inspiratory flow (FIF50%)
Inspiratory-expiratory Flow Volume Loops were measured
using a KoKo K323200 Spirometer (Technipro, North Parra-
matta, Australia). Forced expiratory and inspiratory times
were held constant to ensure consistency and accuracy.
Hypertonic saline challenge for bronchial
hyperresponsiveness, extrathoracic airway
hyperresponsiveness and cough reflex sensitivity
Hypertonic saline challenge for BHR and EAHR has been
described previously.27 Bronchial hyperresponsiveness, was
calculated as the dose response slope (DRS), according to
the percent fall in FEV1 divided by the cumulative dose of
hypertonic saline (mL) delivered. Extrathoracic Airway
Hyperresponsiveness DRS was calculated by dividing the
percent fall in FIF50%, by the cumulative dose of hypertonic
saline (mL) delivered. Cough Reflex Sensitivity was also
calculated as DRS: cumulative number of coughs divided by
the cumulative dose of hypertonic saline (mL) delivered.
The participant’s perceived urge to cough28 at cumulative
15 coughs was also recorded. Cough frequency was definedas the number of coughs recorded during the visit on the
cough monitor and expressed as coughs/hr.
Statistical analysis
Data analysis was conducted using STATA statistical soft-
ware (Statacorp, Texas, USA). Dichotomous categorical
variables were tested by Pearson’s chi2 with Fishers’ exact
test. Continuous non-parametric data analyses were tested
using the KruskaleWallis2 Test for comparison of more than
2 groups. Continuous parametric data were tested using
ANOVA with Bonferroni correction. A p- value result of less
than 0.05 was considered statistically significant.
Results
Current symptoms questionnaire (letter)
responding participant characteristics
From the 136 participants who returned the completed
symptoms questionnaire, 58 (43%) tested positive for H1N1
and 78 (57%) tested negative for H1N1. H1N1 infected
participants were on average 15 years younger than the
H1N1 negative group (p Z 0.0001, Table 1) and included
a greater proportion of females (pZ 0.013, Table 1). There
was a high prevalence of ongoing symptoms present at
a median of 3 months after the acute respiratory illness.
43% of positive for H1N1 participants reported chronic
cough with moderate severity, 26% reported ongoing dysp-
noea and 28% reported ongoing voice symptoms. Similarly,
36% of negative for H1N1 participants reported chronic
cough with moderate severity, 31% reported dyspnoea, and
17% reported ongoing voice symptoms. The youngest age
group (participants less than 40 years of age, median age 22
years) had the highest H1N1 prevalence of 60%, and 50% of
those had persisting cough compared to 23% without
a confirmed H1N1 respiratory infection, p Z 0.12. The
oldest age group (age >60 years, median age of 72 years)
had the lowest prevalence of H1N1 at 17.8%.
Not all patients with H1N1 infection developed a chronic
cough however, for those that do cough reflex hypersensi-
tivity was found to be still prevalent 220 days after
confirmed infection (Table 2).
Clinical testing
19 participants attended for clinical testing, of whom 6
(32%) were positive for H1N1 and chronic cough, 6 (32%)
were positive for H1N1 with no cough, and 7 (37%) were
negative for H1N1 with no cough (healthy controls). These
participants were tested a median (IQR) 221(40) days after
laboratory PCR testing for H1N1 influenza, and 113(46) days
after their questionnaire (letter) responses.
The characteristics and associated mechanisms of post-
infectious chronic cough was examined in the 6 participants
with laboratory-confirmed H1N1 influenza and CC and
compared to those with no cough after laboratory-
confirmed H1N1 infection and to the healthy control group.
Participants with postinfectious chronic cough had height-
ened cough reflex sensitivity compared to participants
without cough (p Z 0.020) and compared with the control
group (Table 2, Fig. 1). They had an increased urge to cough
Table 2 Characteristics and associated risk factors of postinfectious chronic cough following H1N1 influenza infection
compared with no cough following H1N1 influenza infection and healthy controls.
Control Pos H1N1þNeg CC Pos H1N1þPos CC p-value
N 7 6 6
Age, Mean  SD 54.7  22.5 46.7  11.6 35.5  12.8 0.154
Gender M/F, n 4/3 1/5 2/4 0.427
Time, days (swab to clinic testing) 236 (56) 203 (91) 223 (33) 0.116
ACE-I use, % 14.3 16.7 0 1.000
Berlin risk for sleep apnoea, % 28.6 50.0 50.0 0.722
GORD Score, Median (IQR) 11 (16) 14 (6) 13 (12) 0.874
SNOT-20 Score, Median (IQR) 0.3 (0.2) 1.13 (1.60) 1.45 (1.00) 0.186
FEV1 %pred, Mean  SD 99.4  13.9 103.0  11.3 86.3  20.3 0.175
FVC %pred, Mean  SD 100.2  14.4 102.8  13.8 85.6  16.9 0.132
FEV1/FVC%, Mean  SD 81.9  4.8 83.1  3.1 84.1  7.5 0.781
FIF50 %pred, Mean  SD 117.2  22.1 129.4  15.5 105.6  39.2 0.343
Cough Frequency during hypertonic
saline challenge, (calculated as
coughs/hr), Mean  SD
42.3  33.7 56.2  62.6 162.8  168.5 0.108
Leicester Cough Questionnaire,
GMean (95% CI)
20.16 (19.26, 21.11) 20.27 (19.39, 21.19) 18.27 (16.32, 20.46)b 0.036
Laryngeal Dysfunction Questionnaire,
Median (IQR)
3 (3) 2 (4) 6.5 (2) 0.056
BHR-DRS, Median (IQR) 2.29 (3.17) 0.294 (0.359) 1.09 (2.97) 0.157
EAHR-DRS, Median (IQR) 1.53 (11.01) 1.58 (0.868) 5.01 (12.3) 0.246
CRS-DRS, GMean (95% CI) 3.33 (1.41, 7.84) 1.16 (0.24, 5.64) 11.07 (2.79, 43.92)a 0.022
Urge to Cough at PDCUM15Coughs,
Median (IQR)
3 (1) 2.5 (2) 4.5 (1)b 0.050
Cough Severity, Median (IQR) 0 0 17 (11)a 0.003
ACE-I Z Angiotensin conversion enzyme inhibitor, GORD Z Gastrooesaphageal reflux disease, SNOT-20 Z Sino Nasal Outcome Test,
FIF50% Z mid inspiratory flow, DRS Z Dose Response Slope, EAHR Z Extrathoracic Airway Hyperresponsiveness.
a v Pos H1N1þ Neg CC, p  0.020.
b v Pos H1N1þNeg CC, p < 0.05.
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Figure 1 A comparison of cough reflex sensitivity across the
three study groups Control (no H1N1 or cough) v positive H1N1
infection without cough v positive H1N1 infection with chronic
cough.
Postinfectious H1N1 chronic cough 141(p < 0.05 v participants without postinfectious H1N1 cough)
and increased cough severity, p Z 0.003 (Table 2). Objec-
tively measured cough frequency during testing was 3 times
greater in the participants with postinfectious H1N1 chronic
cough compared to the participants without postinfectious
H1N1 cough and 4 times greater than the healthy control
participants (Fig. 3) however this was not significant. The
postinfectious H1N1 chronic cough participants also dis-
played decreased quality of life compared to the partici-
pants without postinfectious H1N1 cough, and compared to
the healthy control participants, pZ 0.036 (Table 2,Fig. 2).
Participants with postinfectious H1N1 chronic cough tended
to have more laryngeal symptoms and increased extra-
thoracic airway hyperresponsiveness than the participants
without postinfectious H1N1 CC and healthy control
participants (Table 2) but this was not significant.
There was no difference in associated risk factors
between the three groups and spirometry was unremark-
able (Table 2).
Discussion
This study reports the first evaluation of chronic cough
following the pandemic H1N1 influenza outbreak in 2009.
We found that participants experience moderate chronic
cough severity after infection but this tended to improve
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Figure 2 A comparison of cough quality of life, LCQ across
the three study groups Control (no H1N1 or cough) v positive
H1N1 infection without cough v positive H1N1 infection with
chronic cough.
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Figure 3 A comparison of cough frequency during clinic
testing across the three study groups Control (no H1N1 or
cough) v positive H1N1 infection without cough v positive H1N1
infection with chronic cough, coughs per hour, Mean  SD.
142 N.M. Ryan et al.spontaneously over time. The characteristics of postH1N1
chronic cough were similar to other postinfectious chronic
cough29 and associated with cough reflex hypersensitivity.
Cough reflex sensitivity, the urge to cough and cough
severity were all enhanced in the participants with post-
infectious H1N1 chronic cough compared to the participants
without postinfectious H1N1 cough and compared to the
healthy control participants. The objectively measured
cough frequency during clinical testing in this current study
was similar to what we have previously observed in the
cough clinic.30 Although the quality of life impairment in
post infectious H1N1 chronic cough was significant, it was
not as severe as seen in people with chronic cough pre-
senting to specialist cough centres.18,20,31 Similarly, the
prevalence of specific cougherelated co morbidities of
reflux, rhinitis, and vocal disturbance was also much lower
than in cough referral clinics. This indicates that although
postinfectious cough is common, it usually causes less
distress than cough from other causes. Our data support the
hypothesis that seeking medical attention for chronic cough
requires additional factors such as a related co-morbidity,
for example GORD, rhinitis, asthma or a voice disorder.
This would also explain why therapy targeting these
conditions, as in the anatomic-diagnostic protocol, is so
successful in treating chronic cough in the cough clinic
setting.1 While these statistical results are significant, they
should be interpreted as merely descriptive due to the
small sample size, a recognised limitation of this study.
The pathogenesis of postinfectious cough is believed to be
related to inflammation and epithelial damage to the upper
and lower airways. Several potential mechanisms for post-
infectious cough have been proposed. These includepostinfectious bronchial hyperresponsiveness4; transient
vocal cord dysfunction3; cough reflex hypersensitivity32;
nasal and sinus inflammation33; and GORD.34 We examined
several of these mechanisms in this study and our results
support increased cough reflex sensitivity as the dominant
mechanism for postinfectious H1N1chronic cough since there
was a 3e9-fold increase in cough reflex sensitivity and no
significant increase in bronchial or extrathoracic hyper-
responsiveness in the postinfectious H1N1 chronic cough
participants comparedwith thehealthyparticipants andpost
H1N1without coughparticipants. Theothermechanismsmay
be relevant in individual patients, but do not emerge as
a general mechanism for postinfectious chronic cough.
Relevant treatment strategies for postH1N1 infectious
chronic cough include components of a diagnostic assess-
ment approach.35 Vaccination appears to be effective at
reducing post pertussis chronic cough.36 An inactivated,
split-virus 2009 H1N1 vaccine is available and is both immu-
nogenic and safe in healthy adults.37 The efficacy of this
vaccine in reducing cough prevalence needs further study.
Limitations of this study include the low response rate to
the questionnaire (current symptoms letter). An over
representation of participants with cough in the response
group is noted as a potential bias. To some extent this was
accounted for in the clinical testing arm of the study where
an even representation of cough, no cough and healthy
controls were tested. It is recommended however that
future studies aim for a more representative group. A
second limitation of this study is that participants were only
clinically tested on one occasion; a preferred scenario
would be to conduct longitudinal testing enhancing char-
acterisation of this group. A third recognised limitation of
this study was that we did not conduct treatment on the
participants therefore we cannot prove causes of the
persistent cough.
Postinfectious H1N1 chronic cough 143In conclusion, this is the first study to evaluate chronic
cough following the pandemic H1N1 influenza outbreak of
2009. H1N1 infected participants were younger, primarily
female and tended to have a higher prevalence of chronic
cough and voice symptoms than those without H1N1. Clin-
ical testing showed that those participants with H1N1
postinfectious chronic cough were still symptomatic with
increased cough reflex sensitivity some 220 days after
infection although cough severity was found to be signifi-
cantly improving by this stage. The characteristics of
postH1N1 chronic cough are similar to other postinfectious
cough and associated with cough reflex hypersensitivity.
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